evipedia.ai
← Back

Sarcosine for Health & Longevity

Evidence Review created on 11/03/2026 using AI4L / Opus 5.5

Also known as: N-methylglycine, Methylglycine, 2-(methylamino)acetic acid

Motivation

Sarcosine (N-methylglycine) is a small natural compound that the body makes from the amino acid glycine and from the nutrient choline, and it also occurs in foods such as egg yolks and turkey. It is sold as an inexpensive dietary supplement. Its best-studied action is to increase the glycine available to a brain receptor involved in learning, memory and mood.

For about two decades, psychiatric researchers have tested sarcosine as an add-on to standard medicines for mental illness. More recently, aging researchers began studying blood sarcosine across the lifespan and under calorie restriction in animals, which drew the attention of people pursuing healthy longevity. Prostate cancer research has also examined the compound, which places safety alongside benefit in any assessment.

This review examines the human and laboratory evidence on what sarcosine may offer and what it may cost health-focused adults, how it has been dosed in studies, what can be monitored during use, and where open questions remain.

Benefits - Risks - Protocol - Conclusion

Expert commentary and narrative reviews that give a high-level overview of sarcosine for aging, muscle, mood and psychiatric use.

Fight Aging! commentary on a 2018 metabolomics (large-scale metabolite profiling) study linking blood sarcosine to aging and calorie restriction, framed around autophagy (the cell’s self-recycling process).

A scientist’s summary of 2025 cohort and mouse data tying sarcosine to sarcopenia (age-related muscle loss), stressing that no human muscle trials exist; part of the analysis is paywalled.

Editorial arguing that sarcosine, freely sold as a supplement, is a rational add-on to antipsychotics (medicines for psychosis) because it boosts the NMDA receptor (N-methyl-D-aspartate receptor, a learning-related brain receptor).

Narrative review comparing sarcosine with ketamine for depression. Co-author Hsien-Yuan Lane led most sarcosine trials with Guochuan Tsai, co-inventor on US patent 6228875 covering its use.

Only four items are listed: none of the six priority experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension, Lifespan.io) has published content on sarcosine, and the remaining candidates were systematic reviews, database pages or primary studies covered in other sections.

Grokipedia

AI-generated encyclopedia entry covering chemistry, one-carbon metabolism (the network that transfers single-carbon units), history since 1847, and research on schizophrenia, prostate cancer and aging.

Examine

Examine’s evidence page grades schizophrenia symptom data, lists a standard 30 mg/kg daily dose, and notes unresolved prostate cancer questions and unknown long-term safety.

ConsumerLab

No ConsumerLab article on sarcosine exists; a direct search of consumerlab.com returned no results as of 11/03/2026.

Systematic Reviews

Systematic reviews and meta-analyses of sarcosine, all in schizophrenia, the only condition with enough trials to pool.

Seven trials, 326 participants: symptoms improved versus comparators, cognition did not significantly. Senior author Lane co-led most included trials.

Independent analysis of six trials: no significant overall effect, owing to heterogeneity (inconsistency between trials); benefit only in chronic, non-clozapine subgroups.

Network meta-analysis (comparing many treatments at once) of 22 supplements: sarcosine outperformed placebo; adverse-event dropouts matched placebo; evidence certainty low to very low.

Forty trials of seven agents: sarcosine among the better profiles, with satisfactory safety and discontinuation; no benefit alongside clozapine.

148 trials rated with GRADE (a certainty-of-evidence system): sarcosine helped several domains; sarcosine plus benzoate ranked highest for cognition.

For depression, only a Cochrane review of glutamate modulators (drugs acting on the brain’s glutamate signaling system) includes sarcosine, with a single trial, and judges that evidence limited (Dean 2021); no systematic review covers sarcosine for longevity, muscle, or the prostate cancer question; harms appear only as secondary tolerability outcomes in Fornaro 2025 and Goh 2021.

Mechanism of Action

Sarcosine acts through three routes:

  • Glycine transporter blockade: Sarcosine competitively inhibits GlyT1 (glycine transporter type 1, the pump that clears glycine from synapses), raising glycine at the NMDA receptor’s co-agonist site (the spot glycine must occupy to open the receptor); in mouse neurons it also activates that site directly (Zhang 2009). A trial registry record (NCT00538070) also lists System A blockade (a carrier moving small amino acids into cells). Stronger NMDA signaling is the proposed basis of its psychiatric effects.
  • Methyl balance: GNMT (glycine N-methyltransferase, the enzyme that makes sarcosine) converts glycine and SAM (S-adenosylmethionine, the main methyl donor) into sarcosine, buffering excess SAM (Obata 2015). SARDH (sarcosine dehydrogenase) and PIPOX (pipecolic acid oxidase) convert it back to glycine (Khan 2013).
  • Aging-related signaling: In cells and rodents, sarcosine induces autophagy (Walters 2018) and activates GCN2 (general control nonderepressible 2, an amino-acid stress sensor) in macrophages (debris-clearing immune cells), shifting them toward tissue repair (Liu 2025).

Competing explanations: Potent synthetic GlyT1 inhibitors failed in large manufacturer-run trials (Roche authors, Bugarski-Kirola 2017), questioning whether this mechanism yields benefit; in prostate cells sarcosine promoted invasion (Sreekumar 2009).

Pharmacology: Oral sarcosine shows linear kinetics (levels rise in proportion to dose), peak levels at 1.5–2.5 hours and a half-life of about 1 hour (Amiaz 2015). It is cleared by SARDH and PIPOX; no CYP (cytochrome P450, the main drug-metabolizing liver enzymes) pathway has been described. GlyT1 sits mainly on brain support cells (Gomeza 2003); human brain penetration has not been quantified.

Historical Context & Evolution

Sarcosine was isolated in 1847 by Justus von Liebig from the breakdown of creatine and named after the Greek word for flesh. For more than a century it was regarded as a minor intermediate of choline and glycine metabolism. Newborn screening found that sarcosinemia (an inherited lack of SARDH that keeps blood sarcosine high) appears largely benign (Levy 1984), an early clue to its tolerability.

Its therapeutic use began in the late 1990s, when Guochuan Tsai and Joseph Coyle patented methods using glycine-site agents, including N-methylglycine, for neuropsychiatric disorders (US patent 6228875, expired 2019). The first controlled trial followed (Tsai 2004), then a series of Taiwanese trials led by Hsien-Yuan Lane and an independent Polish trial (Strzelecki 2016). The pharmaceutical industry pursued more potent synthetic GlyT1 inhibitors, but bitopertin did not separate from placebo in phase 3 (large confirmatory) trials (Bugarski-Kirola 2017).

In 2009, high sarcosine in metastatic (spread) prostate cancer suggested a biomarker and a role in invasion (Sreekumar 2009); later cohorts did not find predictive value (Jentzmik 2011; Ankerst 2015), leaving the question open rather than settled. Longevity interest arose when blood sarcosine was found to fall with age and rise with dietary restriction (Walters 2018) and to be low in sarcopenia (Liu 2025).

Expected Benefits

High 🟩 🟩 🟩

Schizophrenia Symptom Reduction as an Add-on ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

Added at 2 g/day to antipsychotics other than clozapine, sarcosine improved total, negative (blunted emotion, withdrawal and low drive) and general symptoms in trials by the Lane–Tsai group in Taiwan (Lane 2005) and the independent Strzelecki group in Poland (Strzelecki 2016). This bears on treating schizophrenia, not on aging in healthy adults. An independent meta-analysis found no significant pooled effect because trials disagreed (Marchi 2021), and clozapine-treated patients gained nothing (Lane 2006). Net, the larger body of pooled evidence favors a modest benefit in stable patients not taking clozapine.

Magnitude: SMD (standardized mean difference, effect size in standard-deviation units) 0.51 in favor of sarcosine over comparators, 95% CI (confidence interval, the range likely to contain the true value) 0.26–0.76, across 7 trials and 326 participants (Chang 2020).

Depressive Symptom Reduction ⚠️ Conflicted

Sarcosine improved depression ratings in trials from two independent groups: as sole treatment versus citalopram in 40 patients (Lane–Tsai group, Huang 2013), and added to SSRIs (selective serotonin reuptake inhibitors, common antidepressants) in 60 (Padhan group, India, Padhan 2024), via stronger NMDA signaling with higher BDNF (brain-derived neurotrophic factor, a nerve-growth protein). In a 30-patient Parkinson’s dementia trial, gains faded, with no improvement over placebo at 8 weeks (NCT01785628). A Cochrane review judged the evidence limited (Dean 2021). Net, two small trials favor a benefit not yet confirmed at scale.

Magnitude: Score on the Montgomery–Åsberg Depression Rating Scale fell 4.6 points more than with SSRI plus placebo at 8 weeks (95% CI −7.5 to −1.7) (Padhan 2024).

Medium 🟩 🟩

No benefit sits at Medium: the remaining human data are uncontrolled case series, measurements of the body’s own sarcosine levels, or controlled results outweighed by null findings.

Low 🟩

Cognitive Function ⚠️ Conflicted

Pooled schizophrenia trials showed no significant cognitive gain (Chang 2020), and sarcosine alone did not improve cognition where sarcosine plus benzoate did (Lin 2017); combination data are indirect. Posted Parkinson’s dementia results show no apparent benefit (NCT01785628). Net, the stronger evidence shows no reliable cognitive effect.

Magnitude: SMD 0.27 versus comparators (95% CI −0.06 to 0.60), not statistically significant (Chang 2020).

Obsessive-Compulsive Symptom Reduction ⭕️ Not Central to Health & Longevity

In a 10-week open-label (unblinded) study of 26 outpatients, 500–2000 mg/day reduced obsessive-compulsive severity, with 8 of 25 analyzed participants responding; treatment-naive participants (never previously treated with medication) responded more often, but not significantly (Wu 2011). This bears on treating obsessive-compulsive disorder, not on aging. No placebo-controlled trial exists.

Magnitude: Y-BOCS (Yale-Brown Obsessive Compulsive Scale) score fell from 27.6 to 22.7, a 19.8% mean reduction (no control group) (Wu 2011).

Muscle Preservation With Aging

Across two cohorts of 1,013 people, plasma sarcosine was lower in older adults and in sarcopenia; in aged mice, supplementation maintained muscle mass and sped regeneration via repair-oriented macrophages (Liu 2025). The human data concern the body’s own levels, not supplementation, so they are indirect.

Magnitude: Lower plasma sarcosine accompanied aging and sarcopenia in both cohorts; the literature reports no outcome figure for sarcosine intake in humans (Liu 2025).

Speculative 🟨

Autophagy and Dietary-Restriction Signaling

Sarcosine induced autophagy in cultured cells and rodents and rises under dietary restriction (Walters 2018); boosting its producing enzyme extended fly lifespan (Obata 2015). The basis is mechanistic only.

Immune-Cell Migration ⭕️ Not Central to Health & Longevity

Sarcosine-treated dendritic cells (immune messenger cells) migrated better and improved tumor control in mouse vaccine models (Dastmalchi 2019). This bears on cancer-vaccine engineering, not oral use; the basis is laboratory only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic study exists. Inherited SARDH deficiency raises baseline sarcosine (Levy 1984), so carriers may reach higher exposure from the same dose; whether this changes benefit is unknown.
  • Baseline biomarker levels: Lower plasma sarcosine in older and sarcopenic adults (Liu 2025) suggests room for repletion, untested in humans. In a schizophrenia meta-analysis, trials with lower baseline PANSS (Positive and Negative Syndrome Scale, a symptom-severity scale) scores of 70–79 showed larger effects (Chang 2020).
  • Sex: In a meta-analysis, effects trended larger in trials enrolling more women, without statistical significance (Chang 2020); no sex-specific analysis exists for depression, cognition or aging outcomes.
  • Pre-existing conditions: Clozapine-treated and treatment-resistant schizophrenia showed no benefit (Lane 2006; meta-analysis Marchi 2021); a network meta-analysis found stable patients benefited most (Fornaro 2025). Drug-free acutely ill patients responded more often at 2 g than 1 g, though not significantly over time (Lane 2008).
  • Age: Trials enrolled adults mostly aged 18–65, and in a meta-analysis shorter illness duration trended with larger effects (Chang 2020). In older adults with Parkinson’s disease dementia, overall Parkinson’s scores did not improve, while depression and neuropsychiatric symptoms improved temporarily (Tsai 2014).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from small trials reporting tolerability similar to placebo, and other signals rest on case reports, analogue drugs or laboratory studies.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial or comparative observational study has shown a harm of sarcosine itself; the signals are case reports, analogue-drug data or the body’s own sarcosine levels.

Low 🟥

Mood Elevation and Irritability With Serotonergic Antidepressants ⚠️ Conflicted

Two case reports describe irritability or hypomania (an elevated, driven mood state) after 2 g/day was added to antidepressants plus antipsychotics, resolving with dose reduction (Strzelecki 2014; Strzelecki 2015). A 60-person add-on trial with SSRIs reported sarcosine safe (Padhan 2024). Net, the signal is plausible but rare.

Magnitude: Not quantified in available studies. Only two single-patient case reports describe this event, so no rate can be derived.

Headache and Dizziness ⚠️ Conflicted

Transient headache led one participant to withdraw from an open-label study (Wu 2011), and dizziness appeared in a small placebo-controlled trial (NCT01785628). Pooled trials found adverse-event dropouts no different from placebo (Fornaro 2025). Net, these effects are mild and infrequent.

Magnitude: Dizziness in 1 of 15 on sarcosine versus 0 of 15 on placebo (NCT01785628); headache withdrawal in 1 of 26 participants (no control group) (Wu 2011).

Lower Hemoglobin (GlyT1-Inhibitor Class Effect)

Hemoglobin reduction is considered a class effect of GlyT1 inhibitors and was mild and reversible with iclepertin in a pooled overview of its trials (Nagy 2026, authored by employees of its manufacturer, Boehringer Ingelheim). Sarcosine trials have not reported hemoglobin, so this evidence is indirect (analogue compound).

Magnitude: With iclepertin, hemoglobin fell by a mean 2.4 g/L from baseline within 18 weeks, while placebo values stayed stable with small fluctuations (not compared between groups) (Nagy 2026).

Prostate Cancer Progression ⚠️ Conflicted

Sarcosine made benign prostate cells invasive in culture and chick embryos (Sreekumar 2009; Khan 2013). In humans, higher natural serum sarcosine tracked non-aggressive cancer (Koutros 2013), tissue levels were unrelated to aggressiveness (Jentzmik 2011), and serum levels did not predict cancer (Ankerst 2015). Net, the risk is unproven but unresolved.

Magnitude: For natural serum levels, not intake, the highest versus lowest quartile (top versus bottom quarter of levels) had an odds ratio (OR, the relative odds of disease) of 1.30 for prostate cancer (95% CI 1.02–1.65) and 1.03 for aggressive disease (95% CI 0.73–1.47) (Koutros 2013).

Speculative 🟨

Suppressed Breathing Rhythm at High Glycine Exposure

Sarcosine suppressed respiratory rhythm in mouse brainstem slices, and newborn mice lacking GlyT1 showed severe respiratory deficits and died within a day (Gomeza 2003). The basis is mechanistic; no human reports exist.

Risk-Modifying Factors

  • Genetic polymorphisms: Inherited SARDH deficiency raises baseline sarcosine (Levy 1984) and may add to supplement exposure; no study has tested supplementation in carriers. No drug-metabolizing gene variants are relevant because no CYP pathway has been described.
  • Baseline biomarker levels: Existing low hemoglobin matters more given the GlyT1 class effect (Nagy 2026); an elevated PSA (prostate-specific antigen, a prostate blood marker) matters more given laboratory invasion data (Khan 2013).
  • Sex: The prostate concern applies only to men (Sreekumar 2009). No sex differences in adverse events have been reported in sarcosine trials.
  • Pre-existing conditions: Schizophrenia treated with serotonergic antidepressants was the setting of both mood-elevation reports (Strzelecki 2014; Strzelecki 2015); diagnosed prostate cancer raises the stakes of the laboratory invasion signal (Sreekumar 2009).
  • Age: Safety data above age 65 are sparse; in the Parkinson’s disease dementia trial of older patients, no serious adverse events occurred among 15 sarcosine recipients (NCT01785628). Prostate cancer prevalence rises with age.

Key Interactions & Contraindications

Documented interactions:

  • Clozapine: Adding 2 g/day produced no symptom improvement beyond clozapine alone in a 20-patient trial, with no added side effects (Lane 2006). Consequence: no benefit; no harmful interaction found.
  • Non-clozapine antipsychotics (risperidone, olanzapine, quetiapine): No interaction found; add-on trials reported good tolerability (Tsai 2004) and no cardiometabolic or body-composition changes over 6 months (Strzelecki 2015).
  • SSRIs (citalopram, sertraline) and SNRIs (serotonin–norepinephrine reuptake inhibitors, another antidepressant class; venlafaxine): An add-on trial with SSRIs reported safety (Padhan 2024); two case reports describe irritability or hypomania, resolved by reducing sarcosine to 1 g or venlafaxine (Strzelecki 2014; Strzelecki 2015).
  • Sodium benzoate (supplement and food preservative): Additive cognitive effect; sarcosine 2 g plus benzoate 1 g improved cognition where sarcosine alone did not (Lin 2017).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Glycine-site agonists (compounds that directly activate the receptor’s glycine site; glycine, D-serine, D-cycloserine): Additive stimulation of the NMDA co-agonist site, inferred from shared receptor action; possible irritability or over-activation. Monitoring mood and sleep, and avoiding high-dose combinations, limits the overlap.
  • Synthetic GlyT1 inhibitors (bitopertin, iclepertin): Shared transporter target, inferred additive glycine elevation and greater hemoglobin reduction. A complete blood count before and during combined use detects the consequence.
  • NMDA antagonists (receptor-blocking drugs; ketamine, esketamine, memantine, dextromethorphan): Opposing actions at the same receptor may blunt either agent’s effect, including over-the-counter dextromethorphan cough products. Separating courses and tracking response limits the issue.
  • Methyl-donor and choline-pathway supplements (betaine, dimethylglycine, choline, SAMe [supplemental S-adenosylmethionine]): SAMe supplies the methyl group GNMT uses to make sarcosine (Obata 2015), and the others break down toward it, inferring a higher sarcosine load of unknown consequence. Counting total intake limits stacking.

Populations who should avoid Sarcosine:

  • Bipolar disorder or prior hypomania or mania: Inferred from the glutamate–serotonin interaction proposed for a case of sarcosine-associated hypomania in schizophrenia (Strzelecki 2015); no bipolar-specific human data.
  • Men with diagnosed prostate cancer, including active surveillance (monitoring without immediate treatment): Inferred from cell and chick-embryo invasion data (Sreekumar 2009; Khan 2013); no human data.
  • Pregnancy and breastfeeding: Inferred from absent human safety data and the role of GlyT1 in newborn breathing control (Gomeza 2003); no human data.
  • Anemia: Inferred from the hemoglobin-lowering class effect of GlyT1 inhibitors (Nagy 2026); no sarcosine-specific data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Lower starting dose: Starting at 1 g/day for 1–2 weeks before 2 g/day mitigates irritability and over-activation; one case resolved after reduction from 2 g to 1 g (Strzelecki 2014).
  • Mood tracking with antidepressants: Weekly ratings of mood, irritability and sleep need during the first 3 months mitigate hypomania risk; a reduced need for sleep after about 10 weeks was the warning sign in one report (Strzelecki 2015).
  • Hemoglobin check: A complete blood count at baseline and 3 months mitigates the GlyT1-class hemoglobin reduction; a value below the laboratory reference range is the usual pause point.
  • Prostate screening in men: A baseline PSA in men over 45 mitigates the prostate-progression concern by identifying those for whom the laboratory signal matters most.
  • Split dosing: Dividing 2 g into 1 g twice daily mitigates headache and dizziness by lowering peak levels, consistent with the roughly 1-hour half-life (Amiaz 2015).
  • No stacking of glycine-site agents: Keeping high-dose glycine, D-serine and synthetic GlyT1 inhibitors out of the regimen mitigates additive receptor over-stimulation and hemoglobin effects.

Therapeutic Protocol

Doses are cited to their source; other parameters without a citation (timing, titration steps, cycling) reflect common practice.

  • Standard dose: 2 g/day, used in every trial pooled by Marchi 2021, set by the Lane–Tsai group (Tsai 2004) and used by the Polish group (Strzelecki 2016).
  • Weight-based dose: 30 mg/kg/day, about 2.0–2.7 g for adults weighing 68–91 kg (Examine sarcosine page); a pediatric trial used the same 0.03 g/kg/day (Tzang 2016).
  • Lower and higher doses: 1 g/day yielded fewer responders than 2 g/day, not significantly over time (Lane 2008); OCD (obsessive-compulsive disorder) used 500–2000 mg flexibly (Wu 2011); 4 g/day was tolerated open-label (Amiaz 2015).
  • Competing approaches: Sarcosine 2 g alone, or sarcosine 2 g plus sodium benzoate 1 g, which ranked highest for cognition in a network meta-analysis (Liang 2025); D-serine 2 g, a direct glycine-site agonist, did not outperform placebo head-to-head (Lane 2005).
  • Popularizers: Psychiatrists Hsien-Yuan Lane (China Medical University, Taiwan) and Guochuan Tsai (Harbor-UCLA Medical Center) developed the regimen; psychiatrist David Curtis proposed wider clinical use (Curtis 2019). No longevity clinic has published a protocol.
  • Half-life: About 1 hour, with peak levels 1.5–2.5 hours after a dose and linear kinetics (Amiaz 2015).
  • Single or split dose: Trials split 2 g into 1 g twice daily, with or without food (NCT00538070; NCT01785628), consistent with the short half-life.
  • Time of day: No study compared timing; twice-daily regimens used morning and evening doses (NCT00538070), and no trial reported sleep disruption.
  • Genetic polymorphisms: No pharmacogenetic dosing data exist. People with SARDH deficiency already carry high sarcosine (Levy 1984); MTHFR (a folate-processing enzyme) variants, relevant to methyl metabolism, are unstudied.
  • Sex differences: No sex-specific dosing exists; a meta-analysis found effects trended larger in trials with more women (Chang 2020).
  • Age: Most trials enrolled adults up to 65; older adults have lower baseline sarcosine (Walters 2018), and a Parkinson’s disease dementia trial used 2 g/day in older patients (NCT01785628).
  • Baseline biomarkers: Plasma sarcosine and glycine are not used to set doses; in the depression trial, sarcosine raised serum glycine and BDNF (Padhan 2024).
  • Pre-existing conditions: Response was absent with clozapine (Lane 2006) and strongest in stable chronic schizophrenia in a network meta-analysis (Fornaro 2025); no trial has tested healthy adults for longevity outcomes.

Discontinuation & Cycling

  • Lifelong or short-term: Trials ran 6 weeks to 6 months (Strzelecki 2016); no data exist on lifelong use, so open-ended use for longevity goes beyond the evidence.
  • Withdrawal effects: None reported; trials stopped sarcosine abruptly without described rebound, although structured follow-up after stopping was rare.
  • Tapering: No tapering protocol has been studied; stepping down from 2 g to 1 g for a week before stopping is common practice.
  • Cycling: No evidence supports cycling; benefit persisted through 6 months of continuous use in the Polish trial (Strzelecki 2016).

Sourcing and Quality

  • Form: Supplement sarcosine is the free amino acid N-methylglycine, sold as powder or 500 mg capsules, the form used in trials (NCT00538070). Sodium lauroyl sarcosinate in toothpaste and cleansers is an unrelated surfactant.
  • Purity and third-party testing: ConsumerLab has not tested sarcosine products, and no USP (United States Pharmacopeia) or NSF (NSF International) certification for sarcosine was found; a certificate of analysis covering identity, heavy metals and microbes is the available quality check.
  • Grade: Chemical-supplier sarcosine is often labeled for research use only; supplement-grade product made under GMP (good manufacturing practice) conditions is the relevant standard for ingestion.
  • Brands: No retail brand has independent clinical or third-party verification for sarcosine; trial material came from research suppliers rather than consumer products.
  • Dietary sources: A trial registry record lists egg yolks and turkey as sources (NCT00538070), and the body produces it from glycine (Obata 2015), so food intake contributes modestly compared with supplement doses.

Practical Considerations

  • Time to effect: Trials measured psychiatric improvement over 6 weeks (Lane 2005), remission came faster than with citalopram (Huang 2013), and early responders with obsessive-compulsive symptoms improved by week 4 (Wu 2011). No time course exists for aging-related outcomes.
  • Common pitfalls: Treating rodent autophagy and muscle findings as proven human longevity effects; expecting gains on clozapine (Lane 2006); confusing sarcosine with sarcosinate surfactants; combining it with serotonergic antidepressants without mood tracking.
  • Regulatory status: Sarcosine is freely sold as a dietary supplement (Curtis 2019); under the Dietary Supplement Health and Education Act, manufacturers are responsible for safety and labeling before marketing, according to the U.S. Food and Drug Administration (FDA dietary supplements page).
  • Cost and research funding: Sarcosine is inexpensive and its use patent expired in 2019 (US patent 6228875); no manufacturer has funded large trials, while patented GlyT1 drugs received industry-scale testing (Bugarski-Kirola 2017). No payer incentive shaping guidance was identified.

Interaction with Foundational Habits

  • Sleep: No direct effect documented. Hypersomnia (excess sleepiness) occurred in 0 of 15 on sarcosine versus 1 of 15 on placebo (NCT01785628); a reduced need for sleep signaled hypomania in one case report (Strzelecki 2015), making sleep duration a useful warning sign.
  • Nutrition: Indirect interaction. Dietary restriction raised circulating sarcosine in rodents and humans (Walters 2018), and dietary glycine, choline and protein supply the body’s own production; egg yolks and turkey add small amounts. No nutrient depletion has been described.
  • Exercise: Possible potentiating effect on recovery; no human data. In mice, sarcosine enhanced muscle regeneration and adipose thermogenesis (heat production by fat tissue) (Liu 2025), suggesting potential support for recovery; no blunting of training adaptation has been reported, and timing around workouts is unstudied.
  • Stress management: Possible indirect support. Sarcosine reduced anxiety-like and depression-like behavior in rodent stress tests and improved human depression ratings (Huang 2013); no cortisol data exist, so effects on the hormonal stress response are unknown.

Monitoring Protocol & Defining Success

Baseline: Before starting, a complete blood count records hemoglobin, men over 45 add a PSA test, and a fasting plasma amino acid panel records glycine and, where available, sarcosine. A written rating of mood, sleep, energy and mental clarity captures the subjective starting point.

Ongoing: Tests are repeated at 4 weeks, at 3 months, then every 6–12 months during continued use. Mood, irritability and sleep need are tracked weekly in the first 3 months, especially alongside antidepressants. Success means sustained improvement in the targeted symptom or marker without falling hemoglobin or rising PSA; no change after 8–12 weeks at 2 g/day suggests non-response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Hemoglobin Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL (standard reference range) Safety check: GlyT1-inhibitor class lowers hemoglobin Part of a complete blood count; no fasting needed; class data from iclepertin (Nagy 2026); ranges vary by laboratory
PSA (men) Below 4.0 ng/mL (standard reference range) Safety check: laboratory data link sarcosine to prostate cancer invasion Rationale from laboratory invasion data (Sreekumar 2009); draw before any prostate examination; no ejaculation or cycling for 48 hours beforehand; age-specific ranges exist
Plasma glycine About 120–470 nmol/mL (standard reference range) Expected to change: sarcosine raised serum glycine Fasting morning amino acid panel; a rise from own baseline confirms biological effect (Padhan 2024); ranges vary by laboratory
Plasma sarcosine 0–4 nmol/mL (standard reference range) Expected to change: confirms absorption and adherence Part of a quantitative plasma amino acid panel; fasting sample; levels decline with age (Walters 2018); supplementation may exceed the range; ranges vary by laboratory

Qualitative markers:

  • Mood and drive: lift in low mood, with attention to irritability or reduced sleep need.
  • Mental clarity: day-to-day focus and memory.
  • Energy and recovery: perceived energy and training recovery.
  • Sleep quality: duration and continuity.

Emerging Research

  • No ongoing trials: A ClinicalTrials.gov search on 11/03/2026 found no recruiting or active sarcosine intervention trials; every registered sarcosine treatment trial is completed or withdrawn, so no new controlled human data are expected soon.
  • Brain glycine imaging trial (NCT00538070): 68-participant randomized trial at Massachusetts General Hospital testing whether 2 g/day raises brain glycine on magnetic resonance spectroscopy; completed 2012, no results posted. A positive result would show oral sarcosine reaches the brain; a null result would weaken the mechanism.
  • Parkinson’s disease dementia trial (NCT01785628): 30-participant, 8-week trial of 2 g/day; completed 2012, results posted: UPDRS (Unified Parkinson’s Disease Rating Scale) 71.6 to 71.3 on sarcosine versus 66.7 to 68.3 on placebo, not compared between groups; published analysis reported temporary depression and neuropsychiatric gains (Tsai 2014).
  • Muscle aging in humans: Mouse data (Liu 2025) await a human randomized trial; a positive trial would raise muscle preservation above Low, while a null result would leave sarcosine without a demonstrated longevity-relevant benefit.
  • Dietary-restriction mimicry: Whether supplementation reproduces the autophagy induction seen in rodents (Walters 2018) is untested in humans; autophagy markers measured during supplementation would strengthen or weaken the aging rationale.
  • GlyT1 class signals: Phase 3 failures of potent GlyT1 inhibitors (Bugarski-Kirola 2017) and their hemoglobin effects (Nagy 2026) weaken the mechanistic case unless trials outside the original research group confirm sarcosine’s benefit.
  • Prostate safety: Existing cohorts examined only natural levels (Ankerst 2015); prospective data on sarcosine intake and prostate outcomes would resolve the main open safety question.

Conclusion

Sarcosine is a natural compound made from glycine and sold as an inexpensive supplement. Its main known action is to increase the glycine available to a brain receptor involved in learning and mood. Almost all human evidence comes from people with psychiatric illness. Small trials from more than one independent group support improvement in low mood and, when added to most medicines for psychosis, in schizophrenia symptoms, although combined reviews of these trials disagree on the latter and people taking one specific psychosis medicine gained nothing. Evidence for sharper thinking is weak and inconsistent.

For health-focused adults interested in longevity, the appeal rests on animal and cell research: blood levels track aging and calorie restriction, and the compound promotes cellular recycling and muscle repair in rodents. No human study has tested sarcosine for aging, muscle or lifespan outcomes, so this rationale remains a hypothesis.

Short-term safety in trials looks reassuring, with side effects similar to placebo. The open questions are rare episodes of mood over-activation alongside certain antidepressants, a possible mild drop in hemoglobin seen with related drugs, and laboratory findings that sarcosine encourages prostate cancer cell spread, which human studies of natural levels have not confirmed.

The evidence base is small, short and concentrated in one research group whose senior investigator co-invented a patent on this use, and no large independent trial has been run. The studies of related drugs, including the hemoglobin findings, were written by employees of the companies developing those drugs.

Top - Benefits - Risks - Protocol